Articles by Robert Rosenheck, MD

Old Versus New Antipsychotics

January 1, 2013

Robert Rosenheck, MD Professor of Psychiatry, Epidemiology and Public Health, and the Child Study Center, Yale Medical School Dr Rosenheck has disclosed he received research support from Pfizer Pharmaceuticals to analyze CATIE data and has served as a consultant to Otsuka Pharmaceuticals on a long acting injectable antipsychotic. Dr. Balt has reviewed this article and found no evidence of bias in this educational activity.

Are the benefits of atypical antipsychotics based in reality? Dr. Rosenheck explains the stark difference between the SGAs of pharmaceutical myth and what has been proven with actual science.

Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Pre-Order! Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound
This comprehensive guide is designed to be a valuable resource for professionals working in...
READ MORE

General Psychiatry
KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything
Read More

General Psychiatry
Psychopharm Secrets: What Patients Won’t Tell You
How to assess med response when the patient reports is a poor guide: long-term mood stabilizers, sleep meds, and rapid cycling.
Listen now